ClinicalTrials.gg
CompletedNCT02230878Updated Jan 24, 2017

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42847922 in Healthy Participants

A Phase 1 interventional study of JNJ-42847922 5 mg and JNJ-42847922 10 mg in Healthy, sponsored by Janssen-Cilag International NV. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-01-24.

Sponsored by Janssen-Cilag International NV (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to investigate the safety, tolerability, pharmacokinetic (the study of the way a drug enters and leaves the blood and tissues over time), dose-proportionality, accumulation, urinary excretion, pharmacodynamics (the study of how drugs act on the body) and sedative effects of JNJ-42847922 in healthy male and female participants.

Read the detailed description

This is a Phase 1, double blind (a medical research study in which neither the researchers nor the participants know what treatment the participants is receiving), randomized (study drug assigned by chance), placebo controlled, multiple ascending dose study. The study will consist of 3 parts: a Screening period (Days -21 to -2), a Double-blind treatment period (Day -1 to Day 11), and a Follow-up period (within 7 to 14 days after last dose administration). In double blind treatment period, participants will be randomly assigned to 5, 10, 20, and 40 milligram (mg) or placebo. Number of participants with any clinically relevant changes (adverse events [AEs], laboratory results,electrocardiogram [ECG], Vital signs, Physical and neurological, sedation \& concentration) and columbia suicide severity rating (CSSR) scale will be evaluated as primary outcome measure. Participants' safety will be monitored throughout the study.

02

Conditions studied

  • Healthy

Keywords

  • JNJ-42847922
  • Phase 1
  • Healthy
  • Placebo
03

In context

Lead sponsor

Janssen-Cilag International NV is the lead sponsor of 67 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women should not be of child bearing potential due to either tubal ligation or hysterectomy or who are (no spontaneous menses for at least 2 years
  • (BMI) between 18 and 30 kilogram per meter square (kg/m\^2) inclusive (BMI=weight/height\^2)
  • Participants must be healthy / medically stable on the basis of clinical laboratory tests performed at screening. If the results of the serum chemistry panel, hematology, or urinalysis are outside the normal reference ranges, retesting of an abnormal lab value(s) that may lead to exclusion will be allowed once during the screening phase
  • Non-smokers (not smoked for 6 months prior to screening)
  • Participant must be willing and able to adhere to the prohibitions and restrictions specified in this protocol

Exclusion criteria

Exclusion Criteria:

  • abnormal values for hematology, serum chemistry or urinalysis at screening or admission
  • Clinically significant abnormal physical or neurological examination, vital signs or 12-lead (ECG) at screening or admission
  • History of or current significant medical illness including (but not limited to) cardiac arrhythmias or other cardiac disease, hematological disease, lipid abnormalities, bronchospastic respiratory disease, diabetes mellitus, renal or hepatic insufficiency, thyroid disease, Parkinson's disease, infection, or any other illness that the Investigator considers should exclude the participant
  • Serology positive for surface antigen (HBsAg), virus (HCV) antibodies or (HIV) antibodies
  • Subjects with a relevant history of a suicide attempt or suicidal behavior. Any recent suicidal ideation within the last 6 months (a level of 4 or 5), or who are at significant risk to commit suicide, as judged by the investigator using the columbia suicide severity rating score (C-SSRS)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    JNJ-42847922, 5 milligram (mg) and Placebo

    Participants will be receive either 5 mg of JNJ-42847922 from Day 1 up to Day 10 or matching placebo from Day 1 up to Day 10.

    Drug: JNJ-42847922 5 mg · Drug: Placebo

  • Experimental
    JNJ-42847922, 10 mg and Placebo

    Participants will be receive either 10 mg of JNJ-42847922 from Day 1 up to Day 10 or matching placebo from Day 1 up to Day 10.

    Drug: JNJ-42847922 10 mg · Drug: Placebo

  • Experimental
    JNJ-42847922, 20 mg and Placebo

    Participants will be receive either 20 mg of JNJ-42847922 from Day 1 up to Day 10 or matching placebo from Day 1 up to Day 10.

    Drug: JNJ-42847922 20 mg · Drug: Placebo

  • Experimental
    JNJ-42847922, 40 mg and Placebo

    Participants will be receive either 40mg of JNJ-42847922 from Day 1 up to Day 10 or matching placebo from Day 1 up to Day 10.

    Drug: JNJ-42847922 40 mg · Drug: Placebo

Interventions

  • Participants will receive 5 mg of JNJ-42847922, from Day 1 up to Day 10.

  • Participants will receive 10 mg of JNJ-42847922, from Day 1 up to Day 10.

  • Participants will receive 20 mg of JNJ-42847922, from Day 1 up to Day 10.

  • Participants will receive 40 mg of JNJ-42847922, from Day 1 up to Day 10 .

  • DrugPlacebo

    Participants will receive matching placebo from Day 1 up to Day 10.

06

What researchers measure

Primary outcomes

  1. Supine and Standing Systolic and Diastolic Blood Pressure (BP)

    BP is the pressure of the blood within the arteries. It is produced primarily by the contraction of the heart muscle. BP measurement is recorded by 2 numbers: systolic BP (SBP, BP when heart is contracting; it is the maximum arterial pressure during contraction of left ventricle) and diastolic BP (DBP, BP when heart is relaxing; it is the minimum arterial pressure during relaxation and dilation of ventricles).

    Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal

  2. Supine and Standing Heart Rate

    Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal

  3. Tympanic Temperature

    Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal

  4. 12 Lead Electrocardiogram (ECG): RR, QRS, PR, QT, QTcB, QTcF Interval

    Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal

  5. Columbia Suicide Severity Rating Scale (C-SSRS)

    Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal

  6. Number of Participants with Adverse Events

    Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal

  7. Number of Participants With Change From Baseline in Laboratory Tests Results

    Laboratory values included Hematology, clinical chemistry and urinalysis.

    Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal

  8. Physical and Neurological Examination

    Physical and neurological examination will be performed.

    Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal

Secondary outcomes

  1. Maximum Plasma Concentration (C[max])

    The C(max) is the maximum plasma concentration which will be observed at the defined time points.

    Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal

  2. Time to Reach the Maximum Plasma Concentration (T[max])

    The T\[max\] is time to reach the observed maximum plasma concentration.

    Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal

  3. Time to Reach Last Quantifiable Plasma Concentration (T[last])

    The T\[last\] is time to reach the observed maximum plasma concentration.

    Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal

  4. Area Under the Plasma Concentration-Time Curve From Time Zero to hour 24 Time (AUC [0-24])

    AUC (0-24) is the area under the plasma concentration-time curve from time 0 to 24 hours post-dose.

    Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal

  5. Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-last])

    AUC (last) is the area under the plasma concentration-time curve from time zero time of the last quantifiable concentration C(last), and C(last) is the last observed quantifiable concentration.

    Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal

  6. Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-infinity])

    AUC (infinity) is the area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z), wherein AUC(last) is area under the plasma concentration-time curve from time zero to last quantifiable time; and C(last) is the last observed quantifiable concentration; and lambda(z) is elimination rate constant.

    Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal

  7. Average Plasma Concentration at Steady-State (C[avg])

    C(avg) is the average plasma concentration at steady state, calculated as AUC 0-24 divided by 24

    Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal

  8. Trough Plasma Concentration (C[trough])

    Trough plasma concentration is the plasma concentration before dosing or at the end of the dosing interval of any dose other than the first dose.

    Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal

  9. Total Clearance (CL/F)

    CL/F is the total clearance of drug after extravascular administration, uncorrected for absolute bioavailability. It is calculated as Dose divided by AUC.

    Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal

  10. Volume of Distribution (Vd/F)

    Vd/F is the volume of distribution after extravascular administration, uncorrected for absolute bioavailability.

    Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal

  11. Elimination Half-life Period (t1/2)

    Elimination half-life associated with the terminal slope (lambda\[z\]) of the semi logarithmic drug concentration-time curve, calculated as 0.693/lambda (z).

    Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal

  12. Terminal slope (Lambda [z])

    Terminal slope is defined by first-order rate constant associated with the terminal portion of the curve, determined as the negative slope of the terminal log-linear phase of the drug concentration-time curve.

    Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal

  13. Mean Residence Time (MRT)

    MRT is the mean residence time calculated as area under the first moment curve at infinity (AUMC\[0-∞\]) divided by AUC\[0-∞\].

    Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal

  14. Amount of Drug Excreted in Urine (Ae)

    Ae is the amount of urine excreted in urine. It is calculated by multiplying the urinary volume with the urinary concentration.

    Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal

  15. Amount of Drug Excreted into Urine During the 24-hour Dosing Interval (Ae[0-24])

    Ae(0-24h) is the amount of drug excreted into urine during the 24-hour dosing interval.

    Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal

  16. Percentage of Drug Excreted in Urine (Ae%dose)

    Ae%dose is the percentage of drug excreted into the urine calculated as (Ae divided by dose)∗100.

    Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal

  17. Renal Clearance (CL[R])

    CL(R) is the renal clearance of the drug, calculated as Ae/AUC\[0-infinity\] on Day 1 or Ae(0-24)/AUC(0-24) on Day 5 and Day 10.

    Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal

Other outcomes

  1. Assessment of Sedation

    Sedation will be assessed using a reaction time (RT) test battery, the Critical Flicker Fusion (CFF) test and body sway.

    Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal

  2. Bond and Lader Visual Analogue Scale (B and L VAS)

    The B and L VAS includes 16 questions with VAS scales to rate subjective feelings.

    Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal

  3. Addiction Research Center Inventory Questionnaire (ARCI-49)

    The ARCI-49 item questionnaire is developed specifically to measure subjective effects of drugs with diverse pharmacological actions.

    Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal

07

Study locations

1 site
  • Berlin, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2014, a primary completion of Nov 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2014
First posted
Sep 3, 2014
Start
May 2014
Primary completionActual
Nov 2014
CompletionActual
Nov 2014
Last update
Jan 24, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02230878
Responsible party
Sponsor
First posted
Sep 3, 2014
Start date
May 2014
Primary completion
Nov 2014
Completion
Nov 2014
Last update
Jan 24, 2017

Study contacts

Janssen-Cilag International NV Clinical Trial
study director · Janssen-Cilag International NV

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Seltorexant

Start the discussion